Clinical trial
SB-480848 In Subjects With Coronary Heart Disease
NCT00269048 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00269048 |
|---|---|
| Title | SB-480848 In Subjects With Coronary Heart Disease |
| Official title | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Atherosclerosis |
| Intervention type | Drug |
| Interventions | SB-480848, placebo |
| Enrollment | 969 |
| Start date | Nov 1, 2005 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Dec 23, 2005 |
| Last update posted | Aug 8, 2016 |
| Countries | Argentina, Australia, Bulgaria, Canada, Denmark, Estonia, France, Germany, Hungary, India, Netherlands, New Zealand and 4 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: